Abstract
Triple-negative breast cancer (TNBC) constitute 10–20% of all breast cancers and are characterized by the lack of hormone receptors (estrogen and progesterone receptors) and HER2/neu expression (1). TNBC are not eligible to hormonotherapy and Herceptin/trastuzumab targeted therapy and are generally associated with poor clinical outcome (2). Anthracycline/taxane-based neoadjuvant chemotherapy is the primary systemic treatment but resistance to this treatment is common and the identification of new potential therapeutic molecules is required to improve the outcome of TNBC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
